Limits...
Can analyses of electronic patient records be independently and externally validated? Study 2--the effect of β-adrenoceptor blocker therapy on cancer survival: a retrospective cohort study.

Springate DA, Ashcroft DM, Kontopantelis E, Doran T, Ryan R, Reeves D - BMJ Open (2015)

Bottom Line: We found a complex pattern of similarities and differences between databases.However, individually the two studies lead to different conclusions regarding the safety of β-blockers and some subgroup effects differed significantly.Single studies using even internally well-validated databases do not guarantee generalisable results, especially for subgroups, and confirmatory studies using at least one other independent data source are strongly recommended.

View Article: PubMed Central - PubMed

Affiliation: NIHR School for Primary Care Research, Centre for Primary Care, Institute of Population, Health, University of Manchester, Manchester, UK Centre for Biostatistics, Institute of Population Health, University of Manchester, Manchester, UK.

Show MeSH

Related in: MedlinePlus

HRs of survival for patients prescribed β-blocker therapy compared with patients prescribed other blood pressure lowering medicines.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4401857&req=5

BMJOPEN2014007299F1: HRs of survival for patients prescribed β-blocker therapy compared with patients prescribed other blood pressure lowering medicines.

Mentions: There was no difference in adjusted mortality rates between patients in the CPRD receiving β-blockers (with or without other BPLM) and those on other BPLMs only (overall HR=1.01, 95%CI 0.91 to 1.13; table 3; figure 1). This compares to a small but statistically significant impact of β-blockers on mortality in DIN (HR=1.18, 95%CI 1.04 to 1.33). However, the Wald test directly comparing these HRs was not statistically significant, although it did approach significance (p=0.063).


Can analyses of electronic patient records be independently and externally validated? Study 2--the effect of β-adrenoceptor blocker therapy on cancer survival: a retrospective cohort study.

Springate DA, Ashcroft DM, Kontopantelis E, Doran T, Ryan R, Reeves D - BMJ Open (2015)

HRs of survival for patients prescribed β-blocker therapy compared with patients prescribed other blood pressure lowering medicines.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4401857&req=5

BMJOPEN2014007299F1: HRs of survival for patients prescribed β-blocker therapy compared with patients prescribed other blood pressure lowering medicines.
Mentions: There was no difference in adjusted mortality rates between patients in the CPRD receiving β-blockers (with or without other BPLM) and those on other BPLMs only (overall HR=1.01, 95%CI 0.91 to 1.13; table 3; figure 1). This compares to a small but statistically significant impact of β-blockers on mortality in DIN (HR=1.18, 95%CI 1.04 to 1.33). However, the Wald test directly comparing these HRs was not statistically significant, although it did approach significance (p=0.063).

Bottom Line: We found a complex pattern of similarities and differences between databases.However, individually the two studies lead to different conclusions regarding the safety of β-blockers and some subgroup effects differed significantly.Single studies using even internally well-validated databases do not guarantee generalisable results, especially for subgroups, and confirmatory studies using at least one other independent data source are strongly recommended.

View Article: PubMed Central - PubMed

Affiliation: NIHR School for Primary Care Research, Centre for Primary Care, Institute of Population, Health, University of Manchester, Manchester, UK Centre for Biostatistics, Institute of Population Health, University of Manchester, Manchester, UK.

Show MeSH
Related in: MedlinePlus